Author at Microdose

Elisabetta Fato

A native Italian, I currently study Biomedical Sciences at Queen Mary University of London. I have been closely following the latest updates in psychedelics research since the beginning of my undergraduate studies. My passion for science and writing allowed me to write articles published by the British Pharmacological Society and Neurosight, now available on their online magazine and blog respectively. In the future, I am determined to pursue a research career in Neuroscience and Neuropsychopharmacology for the study of Human Consciousness, and I truly believe in the potential of psychedelics as tools that could be used for the investigation of its nature.

Science

8 Jun 2022

Psychedelics for a Healthier Mind and Lifestyle

Psychedelics have been shown to effectively deal with mental health issues, could they be used as prevention by acting on our general lifestyle and everyday behaviour?...

By Elisabetta Fato

Science

1 Jun 2022

A Deeper Look at DMT Trials & Studies

Preliminary results from Phase I clinical trials on DMT for major depressive disorder (MDD) support the safety and tolerability of the compound....

By Elisabetta Fato

Science

9 May 2022

Science Feature: Psilocybin For Anorexia

As depressive and anxiety states often co-occur with eating disorders such as anorexia nervosa, research is now being conducted to find out whether psychedelics could be employed for the treatment...

By Elisabetta Fato

Science

1 Apr 2022

Connecting to Nature Through Psychedelics

Many of the ecological initiatives we still celebrate today, like Earth Day, have their origins in the popularity of psychedelics...

By Elisabetta Fato

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

1 Feb 2022

Science Feature: Re-Inventing Creativity With Psychedelics

How are psychedelics connected to the brain mechanisms to create creativity? What is the evidence of their beneficial effects on creative processes? Could these drugs help scientists grasp the nature...

By Elisabetta Fato

Science

28 Dec 2021

Psychedelics: a non-addictive hope for addiction

Clinical trials testing psychedelics’ effects on tobacco and alcohol addiction, as well as on other substance use disorders, are currently being conducted to investigate their effectiveness at a more global...

By Elisabetta Fato

Science

8 Dec 2021

Science Feature: A Look at the 5HT-2A Receptor

Spend enough time in the psychedelic medicine space — as either an investor or advocate or enthusiast — and you’ll inevitably become familiar with terms like the 5HT-2A receptor....

By Elisabetta Fato

Follow us on social

Latest News

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

WordPress Ads